

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant(s): Henri Tiedge

Examiner: Unassigned

Serial No.: 10/534,789

Group: Unassigned

Filed: May 12, 2005

Docket: 1181-13 PCT US

For: **TRANSLATIONAL CONTROL BY
SMALL, NON-TRANSLATABLE RNAs**

Dated: April 19, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Pursuant to Applicants duty of disclosure, the information listed in the attached Form PTO-1449 is brought to the attention of the Examiner. Copies of the listed publications are submitted herewith.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 19, 2006.

Dated: April 19, 2006


Ann R. Pokalsky

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Inasmuch as this Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits, no fee is due.

Nevertheless, please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 04-1121. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. 04-1121 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to be patentably distinguishable over the prior art and to be in condition for allowance. Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,



Ann R. Pokalsky
Registration No.: 34,697
Attorney for Applicants

DILWORTH & BARRESE, LLP
333 Earle Ovington Boulevard
Uniondale, New York 11553
Tel. No. (516) 228-8484
Fax No. (516) 228-8516
ARP/ml

Form PTO-1449	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1181-13 PCT US	SERIAL NO. 10/5534,789
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANTS Tiedge	
		FILING DATE May 12, 2005	GROUP ART UNIT Unassigned

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		Chen et al., "EXPRESSION OF NEURAL BC200 RNA IN HUMAN TUMOURS", Journal of Pathology, vol. 1, p. 345-351 (1997).
		Lukiw et al., "BC200 IN NORMAL HUMAN NEOCORTEX, NON-ALZHEIMER DEMENTIA (NAD), AND SENILE DEMENTIA OF THE ALZHEIMER TYPE (AD)", Neurochemical Research, vol. 17, pp. 591-597 (1992).
		Iacoangeli et al., "BC200 RNA IN INVASIVE AND PREINVASIVE BREAST CANCER", Carcinogenesis, vol. 25, pp. 2125-2123 (2004).

— 1 —

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.